Product pipeline and R&Dmixed · 4 filings
“27 Table of Contents Income taxes Since inception, we have not recorded any U.S.”10-Q · May 15, 2026 ↗
Outlook Therapeutics, Inc.
OTLK
Market read
Outlook Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
Company+2.9% todayVolume comparison unavailable
Market group0 of 10 activeElectric Vehicle Components · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- OTLK's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if OTLK's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- OTLK's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods6
Price observations319
Usable filing statements71
Verified relationships7
Evidence supporting the case
No qualifying supportive evidence was identified.
Evidence challenging the case
- Latest annual revenue changed -82.6% year over year.
- Operating margin changed -4298.7 percentage points in the latest annual period.
- Net margin changed -3992.4 percentage points in the latest annual period.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 10, 2026
0.666m+56.8%12m-72.2%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2016-09-30$3.0M-42.9%$-3.67—
2017-09-30$3.8M+27.9%$-1.80+39.7%
2018-09-30$3.1M-19.0%$-1.22—
2019-09-30$8.1M+163.8%——
2025-09-30$1.4M-82.6%$-1.79-11.8%
What management says matters
Persistent and emerging business drivers
Restructuring and cost reductionsnegative · 4 filings
“The decrease was primarily due to a $5.0 million combined decrease in cash and stock-based compensation, which was primarily related to severance costs from the departure of our former Chief Executive Officer and reductions in headcount in December 2024.”10-Q · May 15, 2026 ↗
Credit and interest ratesnegative · 2 filings
“This use of cash was partially offset by $9.6 million of non-cash items such as stock-based compensation, non-cash interest expense, change in fair value of promissory notes, warrant related expense, change in fair value of warrant liability, loss on equity m…”10-K · Dec 19, 2025 ↗
Legal and regulatory exposuremixed · 1 filings
“We anticipate that our general and administrative expenses will increase if and when we believe a regulatory approval of a product candidate appears likely, and we anticipate an increase in payroll and expense as a result of our preparation for commercial ope…”10-Q · Aug 14, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 16.2× · EV/sales 10.5×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
0.66+2.9% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for OTLK. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for OTLK. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind OTLK
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
CORCencora, Inc.partnerDec 19, 2025 ▾
“We have entered into a strategic collaboration agreement with Cencora to support the commercial launch of ONS-5010/LYTENAVA globally.”
AMGNAmgen Inc.competitorDec 19, 2025 ▾
“Key competitors include Novartis (Lucentis ® , Beovu ® ), Regeneron (Eylea ® ), Genentech (Vabysmo ® ), Biogen and Coherus (Lucentis ® biosimilars), and Amgen (Eylea ® biosimilar).”
Depended on by
OCGNOcugen, Inc.competitorMar 4, 2026 ▾
“Companies that may compete with our OCU200 product candidate include Roche AG, Regeneron Pharmaceuticals, Inc., AsclepiX Therapeutics, Inc., Outlook Therapeutics, Inc., Novartis AG, Oxurion NV, Unity Biotechnology, Inc., Opthea Limited, and 4D Molecular Thera…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
OTLK is currently a Follower in the organic co-movement group Electric Vehicle Components. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for OTLK; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.